Antioxidant effect of warfarin therapy: A possible symptomatic treatment for erythropoietic protoporphyria

Archives of Dermatology

Volumn 145, Issue 8, 2009, Pages 960-961

  Winship, Ingrid ^a   Ross, Gayle ^b   Nicoll, Amanda ^b   Hogan, Chris ^b   Leong, Yoke ^b   Varigos, George ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ADULT; ANTIOXIDANT ACTIVITY; AORTA VALVE REPLACEMENT; CASE REPORT; DRUG EFFECT; ERYTHROPOIETIC PROTOPORPHYRIA; HUMAN; LETTER; LONG TERM CARE; MALE; PHOTOSENSITIVITY; PRIORITY JOURNAL; SUN EXPOSURE;

ANTIOXIDANTS; HUMANS; MALE; MIDDLE AGED; PHOTOSENSITIVITY DISORDERS; PORPHYRINS; PROTOPORPHYRIA, ERYTHROPOIETIC; WARFARIN;

EID: 68949113849     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.165     Document Type: Letter

References (5)

1. Murphy GM. Diagnosis and management of the erythropoietic porphyrias. Dermatol Ther. 2003;16(1):57-64.
2. Schneider-Yin X, Gouya L, Meier-Weinand A, Deybach JC, Minder EI. New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care. Eur J Pediatr. 2000;159(10):719-725.
3. Payá M, Halliwell B, Hoult J. Interactions of a series of coumarins with reactive oxygen species: scavenging of superoxide, hypochlorous acid and hydroxyl radicals. Biochem Pharmacol. 1992;44(2):205-214.
4. Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, Nicolaides DN. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. Curr Pharm Des. 2004;10(30):3813-3833.
5. Kulkarni MV, Kulkarni GM, Lin CH, Sun CM. Recent advances in coumarins and 1-azacoumarins as versatile biodynamic agents. Curr Med Chem. 2006;13(23):2795-2818.